Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00248547 · ClinicalTrials.gov registry record · NA
Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant
A NA study, sponsored by OHSU Knight Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT00248547 is a NA study that has completed, run by OHSU Knight Cancer Institute. The registered enrollment target is 40 participants.
The verdict
NCT00248547, a NA study, has completed, sponsored by OHSU Knight Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
RATIONALE: Antiemetic drugs, such as aprepitant, ondansetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients undergoing a stem cell transplant. PURPOSE: This randomized clinical trial is studying aprepitant, ondansetron, and dexamethasone to see how well they work compared to placebo, ondansetron, and dexamethasone in preventing nausea and vomiting in patients who are undergoing a stem cell transplant.
Interventions
- DRUG placebo
- DRUG dexamethasone
- DRUG ondansetron
- DRUG aprepitant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2004-05 |
| Est. Completion | 2009-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00248547
The ClinicalTrials.gov registry entry for NCT00248547 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which placebo is the first listed.
NCT00248547 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00248547 about?
NCT00248547 is a clinical study titled "Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant". RATIONALE: Antiemetic drugs, such as aprepitant, ondansetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients undergoing a stem cell transplant. PURPOSE: This randomized clinical trial is studying aprepitant, ondansetron, and dexamethasone to see how well they work com...
What is the current status of trial NCT00248547?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2004-05. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00248547?
The interventions under investigation include: placebo (DRUG), dexamethasone (DRUG), ondansetron (DRUG), aprepitant (DRUG).
Who is sponsoring clinical trial NCT00248547?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.